Amitriptyline for Headache Prophylaxis and Drug Interactions
Amitriptyline is a first-line agent for migraine prevention at doses of 30-150 mg/day, with established efficacy particularly in chronic daily headache and when migraine coexists with tension-type headache. 1
Efficacy for Headache Prevention
Amitriptyline has the strongest evidence base among antidepressants for migraine prophylaxis 1. The medication demonstrates:
- Proven efficacy in reducing headache frequency, duration, and severity in chronic tension-type headache 2
- Superior effectiveness in chronic daily headache (CDH) compared to episodic migraine, with 46% of CDH patients achieving ≥50% improvement in headache frequency at 16 weeks 3
- Particular benefit in patients with mixed migraine and tension-type headache, where it may be superior to propranolol 1
- Comparable efficacy to flunarizine and superior to propranolol for migraine frequency, duration, and severity 4
Clinical Considerations for Use
Start low at 10-30 mg nightly and titrate slowly to 30-150 mg/day over 2-3 months, as clinical benefits may take this long to manifest 1. The sedating effect can be beneficial for patients with comorbid insomnia 5.
Common adverse effects include drowsiness, weight gain, and anticholinergic symptoms (dry mouth, constipation, urinary retention, blurred vision) 1. Elderly patients are particularly sensitive to anticholinergic effects and should start at the lowest doses 6.
Critical Drug Interactions
High-Risk Interactions (Contraindicated or Requiring Extreme Caution)
MAO Inhibitors: Absolutely contraindicated - can cause hyperpyretic crises, severe convulsions, and death 6. Allow at least 14 days after discontinuing MAOIs before starting amitriptyline.
SSRIs (fluoxetine, sertraline, paroxetine): These inhibit CYP2D6 and can increase amitriptyline levels up to 8-fold, potentially causing toxicity 6. When switching from fluoxetine to amitriptyline, wait at least 5 weeks due to fluoxetine's long half-life 6. Monitor for increased anticholinergic effects, sedation, and cardiac effects. Consider dose reduction of amitriptyline by 50% or more when co-prescribed.
Topiramate: Can cause large increases in amitriptyline concentrations 6. Adjust amitriptyline dose based on clinical response, not plasma levels.
Moderate-Risk Interactions (Require Monitoring)
CYP2D6 Inhibitors (quinidine, cimetidine, Type 1C antiarrhythmics like propafenone and flecainide, phenothiazines): Can significantly increase amitriptyline levels 6. Monitor for toxicity and consider dose reduction. When cimetidine is added, anticholinergic side effects increase in frequency and severity 6.
Anticholinergic agents: Risk of hyperpyrexia, particularly in hot weather, and paralytic ileus 6. Close supervision required.
CNS depressants (alcohol, barbiturates, benzodiazepines): Additive sedation and respiratory depression 6.
Sympathomimetic drugs and epinephrine (including in local anesthetics): Requires careful dose adjustment and close supervision 6.
Important Clinical Pitfalls
Switching between antidepressants: The robust evidence for amitriptyline does NOT extend to SSRIs, which are ineffective for headache prevention 2, 7, 5. Don't assume all antidepressants work equally.
Medication overuse: Once preventive treatment begins, avoid overuse of acute medications (>2 days/week), as this can lead to medication-overuse headache 1
Suicide risk: Monitor closely during initial treatment and dose changes, especially in younger patients 6
Pregnancy/lactation: Discuss teratogenic risks with patients of childbearing potential 8, 9
Poor metabolizers: 7-10% of Caucasians are CYP2D6 poor metabolizers and will have much higher drug levels at standard doses 6
When Amitriptyline May Not Be Appropriate
Consider alternative first-line agents (propranolol 80-240 mg/day, timolol 20-30 mg/day, divalproex sodium 500-1500 mg/day) in patients with:
- Cardiac conduction abnormalities
- Urinary retention or narrow-angle glaucoma
- Significant anticholinergic burden from other medications
- Recent MI or unstable cardiac disease 6
Monitor TCA plasma levels whenever co-administering drugs known to inhibit CYP2D6 6.